💊
Global CE Rate
84.1%
▲ 9.9pp above SoC baseline
📊
Median Global ICER
$19.2K
▲ Well below $50K WTP floor
⭐
QALY Gain vs SoC
+0.353
▲ 33.7% QALY improvement
🏥
Survival Gain
+7.0 mo
▲ New Drug vs SoC (all geos)
🌐
Best Market (US)
90.4%
▲ WTP $100K · Tier 1 Priority
Avg Annual Cost — New Drug
$41.0K
▲ +$6.04K vs SoC ($34.98K)
New Drug QALY (Avg)
1.400
▲ vs SoC: 1.047 QALY
CE Rate at $100K WTP
90.3%
▲ Germany · Japan · US
Lowest CE (UK)
76.9%
▼ Requires PAS at £50K WTP
Country Performance Matrix
LIVE DATACE Rate by Country — New Drug vs SoC vs WTP Threshold
HIGH CONFIDENCE
Treatment Value Radar
MULTI-DIM
Survival Advantage by Country
QALY — New Drug vs SoC
ICER Distribution — IQR Box
⬛ CE% Heatmap — Country × Disease Severity (New Drug)
HIGH CONFIDENCE · 49,784 patients
Geographic Intelligence Summary
MARKET ACCESS
| Country | WTP | ND CE% | SoC CE% | Median ICER | QALY | Survival | Δ Cost | Access Tier |
|---|
Sovereign Strategic Recommendations
Germany, US, Japan — WTP $100K markets show 88–90% CE rate for New Drug. Submit at list price with premium AMNOG/HTA dossiers. No price concession required.
UK requires 15% net PAS (Performance-Based Access Scheme) to exceed 80% CE floor under NICE £50K threshold. Negotiate outcomes-linked rebate structure.
India & Brazil — outcomes-based contracting at 18–22% effective rebate with QALY milestone triggers will lift CE above 82%.
China NHSA negotiation with 20–25% reduction positions the New Drug within the ¥50K WTP band; RWE submission package essential.
Cost-Effectiveness Plane Analysis
ICER · INCREMENTAL · QALY◎ Interactive CE Plane — Incremental Cost vs QALY
Cost-Effective (ICER < WTP)
Not Cost-Effective
WTP $50K Line
WTP $100K Line
⚡ Dynamic WTP Explorer
WTP Threshold
$50,000
CEAC — All Countries
WTP Sensitivity — All Markets
QALY Accumulation by Survival Cohort
ICER Waterfall — Country Ranking (Best→Worst)
Utility Score (EQ-5D Proxy) by Severity & Arm
3D Geographic Intelligence Globe
THREE.js · WEBGL · REAL-TIME INTERACTIVETier 1 Markets
3
US · DE · JP · WTP $100K
Tier 2 Markets
4
FR · IN · BR · CN · WTP $50K
Tier 3 / Conditional
1
UK · PAS Required
Total Addressable Pop.
100K
8 geo · balanced sample
◈ Interactive 3D Globe — CE Spikes · ICER Rings · Patient Volume · Drag/Zoom
Tier 1 ≥88% CE
Tier 2 77–88%
Tier 3 <77%
Spike height = CE% · Ring = ICER · Size = n
Market Rankings
Selected Market Detail
← Hover a country spike to inspect
Launch Priority Matrix
New Drug vs SoC Annual Cost by Country
Bubble Matrix — ICER vs CE% · Size=n · Color=Country
Survival Gain (New Drug − SoC) by Geography
3D Cost-Effectiveness Surface Analytics
THREE.js · PARAMETRIC SURFACE · WEBGL · INTERACTIVE⬛ ICER Surface — X: Country (8 geos) · Z: WTP Threshold ($10K–$105K) · Y: P(Cost-Effective) %
Drag to orbit · Scroll to zoom · Click bar for data
100%
75%
50%
⬛ 3D Bar Forest — Country (X) × WTP Level (Z) × CE% (Y · labeled)
Hover bar for exact value
X-Axis:
8 Countries
8 Countries
Z-Axis:
WTP Levels
WTP Levels
Y-Axis:
CE% (0–100)
CE% (0–100)
Color:
Country ID
Country ID
⬛ 3D PSA Cloud — X: ICER ($) · Y: QALY Gain · Z: Annual Cost · Color: Country
CE Surface Heat Lattice — Severity × Country × CE%
3D Surface Interpretation — Key Findings
Probabilistic Sensitivity Analysis — Monte Carlo
5,000 ITERATIONS · BOOTSTRAP PSAMC Iterations
5,000
Bootstrap resampling
P(CE) @ $50K — Best
78.5%
US · Highest at $50K
P(CE) @ $100K — Best
89.6%
US · Target threshold
US Median ICER (PSA)
$19,700
IQR: $3,692–$43,132
Cost-Effectiveness Acceptability Curves (CEAC) — All 8 Countries
HIGH CONFIDENCE
Tornado — Key Driver Analysis
P(CE) @ $50K vs $100K WTP
ICER Confidence Intervals (P5–P95)
⚡ Interactive WTP Explorer — Real-Time CE Probability
DYNAMIC · LIVE
WTP Threshold ($)
$50,000
Forest Plot — Subgroup ICER with 95% CI
HIGH CONFIDENCEPatient Segmentation & Subgroup Intelligence
SUBGROUP · PRECISION MEDICINECE% by Age Group & Sex — New Drug
ICER by Demographic Segment
Comorbidity Impact on CE
D3 Bubble — Segment Priority Matrix
Severity CE% by Country
Optimal Patient Segments — Animated Priority Rings
HIGH CONFIDENCE
Segmentation Strategy Recommendations
Submit Moderate severity label first — US (89.8%), Germany (88.6%), Japan (88.7%) show highest CE rates globally.
Female patients aged 55–70 represent the optimal reimbursement population: $18,967 median ICER with 81.7% CE rate.
Female <40 has highest CE at 83.2% — premium access cohort for early treatment initiation arguments.
Critical severity in Germany (89.0%) and US (89.7%) supports premium pricing with strong HTA justification.
Optimal Pricing & Reimbursement Strategy
VALUE-BASED PRICING · MARKET ACCESSOptimal ICER Target
$18.5–19.8K
Max CE across all geos
Implied Drug Cost
$2,500/mo
At optimal ICER target
Required Rebate (UK/India)
15–20%
To achieve 80% CE floor
CE Lift ($50K→$100K)
+11.9pp
CE acceptability gain
Value-Based Price Corridor by Country
Price Elasticity — CE% vs Drug Monthly Cost
Reimbursement Probability by Rebate
PAS / OBC Scenario Analysis
Competitor ICER Landscape
Country-Level Pricing Strategy Playbook
MEDIUM CONFIDENCE| Country | WTP | Current CE% | Target CE% | Pricing Action | Net Rebate | Access Scheme | Priority Score |
|---|
HEOR Knowledge Graph — Entity Intelligence Network
D3 FORCE GRAPH · NLP ONTOLOGY · LIVE◎ HEOR Knowledge Graph v5 — 47 Nodes · 92 Edges · 10 Communities · Drag · Zoom · Hover
Node size = centrality · Edge weight = relationship strength · Colors = entity type
Graph Statistics
Nodes47
Edges92
Graph Density0.142
Avg Degree4.8
Hub NodeCost-Effectiveness
Communities10
Top Central Nodes
Legend
▸ Evidence NMA Network — SUCRA Rankings
▸ Payer Stakeholder Network — Flow Analysis
▸ HEOR Decision Tree — Reimbursement Path
▸ HEOR Concept Ontology — Hierarchical Taxonomy
ONTOLOGY · D3 TREE▸ Causal Inference DAG — ICER Determinants
CAUSAL · DAG · COEFFICIENTSMCP Sovereign Intelligence Hub
PHASES 4–12 · REAL-TIME SIGNAL INTEGRATION · WAR-GAMING · KOL · rNPVMCP://HEOR-ENGINE
▸ QA_SCORE: 98/100
▸ CONFIDENCE: HIGH
▸ SIGNALS: 47 TRACKED
▸ PHASE: 4–12 ACTIVE
ALL SYSTEMS NOMINAL
Phase 4 · Financial Engine
rNPV (Base)$2.84B
Peak Sales (Yr5)$1.32B
WACC Applied8.5%
PoS Blended84.1%
Optimism Haircut−35%
Phase 5 · War-Gaming
Nash EquilibriumStable
Competitor A MovePrice -12%
Optimal ResponseOBC Scheme
Market Equilib.T+14mo
Win Probability73%
Phase 6 · KOL Network
Tier 1 KOLs28
DOL Sentiment+0.67 positive
Top InfluencerDr. Chen (JP)
Congress CoverageISPOR·ESMO·ASH
Publications (12mo)14 peer-reviewed
Phase 7–12 · Access
GVD Status82% complete
NICE OutcomeTA pending
G-BA TierErheblich A
Portfolio Score91/100
QA Gate98/100 ✓
Phase 4 · Financial Dominance Engine
rNPV · PEAK SALES · BIM · MONTE CARLOrNPV Epidemiology Cascade & Revenue Model
Peak Sales Forecast — Launch Ramp Yr1–8 (3 Scenarios)
Budget Impact Model — 1/3/5-Year Horizons
Monte Carlo Portfolio NPV Distribution (10,000 Iterations)
2-Way Sensitivity — WACC × Market Penetration → rNPV ($B)
Phase 5 · Strategic War-Gaming
NASH EQUILIBRIUM · GAME TREE · PAYOFF MATRIX5-Move Game Tree — Optimal Strategy Path
Pricing Game Matrix — Nash Equilibrium Analysis
Phase 6 · KOL & DOL Sovereign Intelligence Network
FORCE GRAPH · WEDGE LABELS · CONNECTION STRINGS · REAL-TIME SENTIMENT · PAGERANK
KOL CONTROL MATRIX
28 KOLs · 3 Institutions
KOL Influence Network — 28 Nodes · Connection Strings · Wedge Labels · PageRank Sizing · Drag/Zoom
LIVE · APR 2026
◈ HTA Institution
● Tier 1 KOL (PageRank ≥0.80)
● Tier 2 KOL (0.50–0.79)
● Tier 3 KOL (0.30–0.49)
Inner arc = Publications · Mid ring = PageRank · Outer wedge = Specialties
Network Statistics
28
KOL Nodes
42
Edge Connections
0.67
DOL Sentiment
0.142
Graph Density
Hub: Dr. Chen (JP) · PR=0.95
Bridge: Prof. Müller (DE) · B=0.61
Avg Degree: 3.8 · Clustering: 0.42
DOL Sentiment Tracker
KOL Engagement Heatmap
SIGNAL MATRIXTier 1 KOL Profiles — Deep Intelligence
Co-Publication Connection Matrix
ADJACENCYPhase 7–10 · Market Access & Launch Intelligence
GVD · GANTT · HTA TRACKER · FORMULARYGVD Readiness Radar — 7 Dimensions
HTA Decision Tracker — Real-Time Status
Formulary Pull-Through — Access by Tier
36-Month Launch Roadmap — HEOR + Commercial + Regulatory (150+ Milestones)
GANTT · MULTI-FUNCTIONPhase 11–12 · Signal Intelligence & Portfolio Strategy
CLINICALTRIALS · EARNINGS NLP · ASSET MATRIXSignal Feed — ClinicalTrials.gov + Competitor Watch
Portfolio Asset Prioritization Matrix
Scenario Analysis — Opt / Base / Conservative
Claude AI · Live Intelligence Briefing Engine
REAL-TIME · ANTHROPIC API · MORNING BRIEFING · AUTO-UPDATE
CLAUDE · SOVEREIGN HEOR INTELLIGENCE ENGINE
Last update: Never
claude-sonnet-4-20250514
HEOR-SOVEREIGN://claude-api$
System ready. Click MORNING BRIEFING to connect to Claude AI and receive a real-time HEOR intelligence update.
Daily auto-scheduling available. All outputs are generated fresh via Anthropic API.
Live Signal Stream
06:14URGENTComp A Phase III readout delayed to Q4 2026 — window of opportunity extended +6mo
05:42CEG-BA early benefit assessment: "Erheblicher Zusatznutzen" confirmed — premium pricing supported
04:18KOLDr. Chen (JP) published RWE validation n=1,800 — ICER $18,900 consistent with model
03:55PAYERNICE appraisal committee meeting scheduled T−6 weeks — PAS framework discussion imminent
02:30NMANew NMA published: SUCRA rank 1 confirmed across all 5 endpoints — evidence strengthened
01:15SIGNALNHSA China: preliminary dialogue suggests 35% price reduction required for NRDL inclusion
00:40CEPhase IV RWE interim n=1,200: QALY 1.38 in real-world — consistent with Phase III 1.40
Signal Intensity Heatmap
7-DAY ROLLINGUpdate History
No updates yet. Click a briefing button above.
Phase 11 · Advanced Signal Intelligence Matrix
REAL-TIME · NLP · COMPETITOR TRACKINGCompetitor Threat Radar
MULTI-DIMICER Positioning Landscape
COMPETITIVEMarket Access Velocity
TIMELINE◈ Sovereign Intelligence Recommendations — All 12 Phases
HIGH CONFIDENCE · QA 98/100💊 Pricing & Access
Target ICER $18.5–19.8K — favorable at all WTP thresholds globally.
Germany & US at list price. AMNOG tier A anticipated. No concession.
UK: 15% PAS net reduction to pass NICE £50K threshold.
India/Brazil: outcomes-based rebate 18–22% with QALY milestones.
⚔ War-Gaming
Competitor A is price-cutting at −12%; counter with OBC scheme, not price match.
Nash equilibrium reached at T+14mo; market share stabilizes at 34%.
Preemptive patent thicket filing on 3 formulation variants before T−6mo.
Combination therapy barrier study: fund IIT with top-3 KOL centers by T+6.
🧬 KOL Strategy
Engage top 8 PageRank KOLs immediately — Dr. Chen (JP), Prof. Müller (DE) are gatekeepers.
DOL sentiment +0.67 — leverage MedTwitter community for real-world data seeding.
ISPOR + ESMO abstract submissions: 4 posters planned for T−6 conference cycle.
Advisory board: Tier 1 KOL from UK critical — NICE panelist overlap confirmed.
📈 Portfolio / Financial
rNPV $2.84B base; $4.1B optimistic — lifecycle extension adds $680M at T+36.
Budget impact shows $340M savings in hospitalizations over 5 years (payer perspective).
M&A synergy: acquire Phase II asset in adjacent indication for $180M — accretive at 12× EBITDA.
Monte Carlo VaR (5%): rNPV floor $1.2B — downside well-protected vs. $420M R&D investment.